In this context, it is worth noting however that within the same cancer type, there is no current evidence that the status of common mutations appears to have a major impact on EMT-related metabolic reprogramming, as NSCLC cell lines harboring mutant or wild-type KRAS, EGFR, and TP53, as well as breast cancer cell lines with or without HER2 overexpression do not display mutation-specific changes [23, 26]. This evidence concerns the gene ERBB2 and breast cancer.